(Print or Type Responses)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROV	AL
OMB Number:	3235-0287
Estimated average burd	en
hours per response	0.5

longer subject to Section 16. Form 4 or Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Form 5 obligations may Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

GRANGE DAVID L					Z. Issuer Name and Ticker of Trading Symbol Tonix Pharmaceuticals Holding Corp. [TNXP]								(Check all applicable) _X_Director 10% Owner					
(Eirst) (Middle) C/O TONIX PHARMACEUTICALS HOLDING CORP., 26 MAIN STREET, SUITE 101					3. Date of Earliest Transaction (Month/Day/Year) 05/10/2021								Officer (give ti	tle below)	Other (s	pecify below)		
(Street)				4. If A	4. If Amendment, Date Original Filed(Month/Day/Year)							_X_ Fo	6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting Person Form filed by More than One Reporting Person					
	AM, NJ 07																	
(Cit	ty)	(State)	(Zip)		Table I - Non-Derivative Securities Acqu								ired, Disposed of, or Beneficially Owned					
1.Title of Security 2. Transaction Date (Month/Day/Ye		ear) Ex	ecuti y	emed on Date, if /Day/Year)	(Instr. 8)		(A	4. Securities Acquir (A) or Disposed of (Instr. 3, 4 and 5)				curities Beneficially ng Reported		wnership o	7. Nature of Indirect Beneficial Ownership			
			(171	(Wolldin/Day			Code	V A	moui	(A) or (D)	Price	5 and 4)		or (I)		Instr. 4)		
Reminder:	Report on a s	separate line for each	a class of securities b	II - Der	rivati	ive Securiti	ies A	ti c	ersons nis forn urrently	n are y va sed o	o respond to e not required omb co	red to respondent of numbers of the	ond unles er.		contained in displays a	SEC 14	474 (9-02)	
Security	2. Conversion or Exercise Price of Derivative Security	(Month/Day/Year) any	Execution Date, if	Code			Expiration I (Month/Day d of		ion Date	ate		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	Form of Derivative Security: Direct (D) or Indirect	(Instr. 4)	
				Code	v	(A)	(D)	Date Exercis	sable		expiration Date	Title	Amount or Number of Shares		(111511.4)	(IIISII. 4)		
Stock Option	\$ 1.03	05/10/2021		A		270,882		05/10	/2022 <mark>C</mark>	1) 0	5/10/2031	Common Stock	270,882	\$ 0	270,882	D		

Reporting Owners

	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
GRANGE DAVID L C/O TONIX PHARMACEUTICALS HOLDING CORP. 26 MAIN STREET, SUITE 101 CHATHAM, NJ 07928	X					

Signatures

/s/ Jessica Morris, Attorney-in-Fact	05/12/2021
**Signature of Reporting Person	Date

Explanation of Responses:

- If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C.
- (1) The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.